Zenas BioPharma, Inc. Announces Q4 and Full Year 2025 Results and Major Corporate Updates

WALTHAM, Mass., March 16, 2026 – Zenas BioPharma, Inc. (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company focused on transformative therapies for autoimmune diseases, has released its financial results for the fourth quarter and full year ended December 31, 2025, along with important corporate updates. These developments contain several price-sensitive elements that shareholders need to be aware of, with potential to significantly move ZBIO’s share price.

Key Highlights and Potential Share Price Movers

• Obexelimab (Lead Asset):
  • Marketing applications for obexelimab in IgG4-Related Disease (IgG4-RD) are expected to be submitted to the FDA in Q2 2026 and EMA in H2 2026, following highly positive results from the Phase 3 INDIGO trial.
  • Obexelimab achieved a statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo over 52 weeks, meeting its primary and all four key secondary endpoints.
  • Topline results from the global Phase 2 SunStone trial in Systemic Lupus Erythematosus (SLE) are expected in Q4 2026, including biomarker population data.
  • Obexelimab’s unique mechanism inhibits B cell activity without depleting them, offering broad coverage for autoimmune diseases and is administered via subcutaneous injection.
• Pipeline Expansion and Clinical Development:
  • ZB014: A new, half-life extended anti-CD-19 and FcγRIIb monoclonal antibody, leveraging technology to potentially enable once-monthly dosing, is advancing toward clinical development.
  • Orelabrutinib: A highly selective, CNS-penetrant Bruton’s Tyrosine Kinase (BTK) inhibitor. A global Phase 3 trial (PriMroSe) for primary progressive MS (PPMS) is ongoing; a second Phase 3 trial (Monarch) for non-active secondary progressive MS (naSPMS) is expected to start in Q1 2026.
  • ZB021: A novel oral IL-17AA/AF inhibitor with best-in-class potential, Phase 1 trial initiation expected in Q2 2026 with initial clinical data by year-end 2026.
  • ZB022: Oral, brain-penetrant TYK2 inhibitor, IND-enabling studies ongoing with advancement to clinical stage anticipated post-clearance.
• Strategic Financing:
  • Secured up to \$250 million in non-dilutive, multi-tranche debt financing from Pharmakon Advisors, strengthening Zenas’ balance sheet and providing flexibility for commercialization and pipeline investment.
  • The first \$75 million tranche was issued at closing, and additional \$175 million is available subject to regulatory and commercial milestones related to obexelimab through April 2029. Investment funds will receive mid-single digit interest payments over SOFR.
  • Potential receipt of \$75 million from Pharmakon and \$75 million from Royalty Pharma contingent on FDA approval of obexelimab for IgG4-RD, extending cash runway into Q4 2027.

Financial Performance and Position

• Cash, cash equivalents and investments: \$360.5 million as of December 31, 2025.
• Cash position, combined with ATM sales and debt proceeds, is expected to fund operations into Q2 2027; with milestone payments, funding extends into Q4 2027.
• Revenue: \$10.0 million for FY 2025, from a one-time upfront payment by Zai Lab for greater China rights to the thyroid eye disease program. Revenue in 2024 was \$5.0 million from Tenacia Biotechnology.
• R&D Expenses: \$168.1 million for FY 2025, up from \$139.1 million in 2024, driven by increased personnel, development costs, and clinical trial expenses for orelabrutinib and other programs.
• General & Administrative Expenses: \$53.3 million for FY 2025, up from \$29.7 million in 2024, reflecting higher personnel, pre-commercialization, and professional fees.
• Acquired In-Process R&D: \$171.7 million for FY 2025, related to upfront cash and equity payments for the license agreement with InnoCare (orelabrutinib, ZB021, ZB022).
• Net Loss: \$377.7 million for FY 2025, compared to \$157.0 million in 2024. Q4 2025 net loss was \$240.4 million versus \$52.6 million in Q4 2024. Increase driven by acquired in-process R&D, higher operating expenses, and royalty obligations.
• Royalty obligation: \$78.6 million as of December 31, 2025.
• Total liabilities: \$141.5 million as of December 31, 2025, up from \$57.5 million in 2024.
• Total stockholders’ equity: \$242.1 million as of December 31, 2025, versus \$312.5 million at year-end 2024.

Other Important Investor Information

• Major regulatory milestones are imminent, including FDA and EMA submissions for obexelimab, which could be catalysts for share price movement.
• Positive top-line Phase 3 data for obexelimab in IgG4-RD, and anticipated data from other pipeline products (ZB014, orelabrutinib, ZB021, ZB022), are likely to impact investor sentiment and valuation.
• Strategic non-dilutive financing and potential milestone payments provide financial stability and flexibility, important for commercialization and continued pipeline progression.
• Risks disclosed include clinical trial uncertainties, regulatory approval challenges, reliance on third-party manufacturers (notably WuXi Biologics and InnoCare in China), and substantial losses leading to concerns about going concern status.
• Company’s independent auditor has expressed substantial doubt regarding Zenas’ ability to continue as a going concern in its report for FY 2025 financials.

Outlook and Potential Catalysts

• Investors should closely monitor upcoming FDA and EMA regulatory submissions for obexelimab, as approval would unlock milestone payments and commercialization potential.
• Further clinical trial readouts in SLE (SunStone) and MS (PriMroSe/Monarch) are expected in 2026, which could be significant value drivers.
• Progression of next-generation assets (ZB014, ZB021, ZB022) and continued expansion of the pipeline may provide upside opportunities.
• Financial stability via debt financing and milestone payments reduces dilution risk and supports long-term growth.

Conclusion

Zenas BioPharma’s Q4 and FY 2025 results reflect significant clinical, regulatory, and financial progress. The company is positioned for upcoming catalysts in 2026, including regulatory submissions, clinical trial results, and pipeline expansion. While positive developments could drive substantial upside, risks remain regarding clinical outcomes, regulatory approvals, and ongoing financial losses. Shareholders should closely track these milestones and the company’s ability to secure additional funding and achieve commercialization.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All forward-looking statements may be subject to risks and uncertainties, including but not limited to those described by Zenas BioPharma in its filings with the U.S. Securities and Exchange Commission. Investors are urged to conduct their own research and consult with professional advisors before making investment decisions.

View Zenas BioPharma, Inc. Historical chart here